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OBJECTIVEdTo compare three continuous glucose monitoring (CGM) devices in subjects
with type 1 diabetes under closed-loop blood glucose (BG) control.
RESEARCHDESIGNANDMETHODSdSix subjects with type 1 diabetes (age 526 14
years, diabetes duration 32 6 14 years) each participated in two 51-h closed-loop BG control
experiments in the hospital. Venous plasma glucose (PG) measurements (GlucoScout, Interna-
tional Biomedical) obtained every 15 min (2,360 values) were paired in time with corresponding
CGM glucose (CGMG) measurements obtained from three CGM devices, the Navigator (Abbott
Diabetes Care), the Seven Plus (DexCom), and the Guardian (Medtronic), worn simultaneously
by each subject. Errors in paired PG–CGMGmeasurements and data reporting percentages were
obtained for each CGM device.
RESULTSdThe Navigator had the best overall accuracy, with an aggregate mean absolute
relative difference (MARD) of all paired points of 11.8 6 11.1% and an average MARD across
all 12 experiments of 11.86 3.8%. The Seven Plus and Guardian produced aggregate MARDs of
all paired points of 16.56 17.8% and 20.36 18.0%, respectively, and average MARDs across all
12 experiments of 16.5 6 6.7% and 20.2 6 6.8%, respectively. Data reporting percentages,
a measure of reliability, were 76% for the Seven Plus and nearly 100% for the Navigator
and Guardian.
CONCLUSIONSdA comprehensive head-to-head-to-head comparison of three CGM devices
for BG values from 36 to 563 mg/dL revealed marked differences in performance characteristics
that include accuracy, precision, and reliability. The Navigator outperformed the other two in
these areas.
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W idely accepted clinical standardsfor accuracy and reliability of thecommercially available continu-
ous glucose monitoring (CGM) devices
have not yet been established by pro-
fessional associations or regulatory agen-
cies. To generate such standards, the
accumulation of large datasets comparing
reference-quality blood glucose (BG) or
plasma glucose (PG) measurements with
CGM glucose (CGMG) data is needed.
Most investigator-initiated studies that
have attempted to gather such data have
been relatively short in duration (usually
several hours), contained low data den-
sity, and/or have not included large var-
iations in glucose values or large time
rates of change in glucose values that are
typical of diabetes (1–3). There is a dearth
of studies comparing CGM devices worn
simultaneously by the same subject, and
those that exist have suffered from the
same limitations (3). Data obtained by
CGM device manufacturers cannot be
directly compared across devices owing
to differences in the clinical protocols
between studies.
There is a clear and present need to
evaluate the relative accuracy and reliability
of the commercially available CGM devices
over large ranges of BG values and time
rates of change in BG values, and over
sensor wear periods that are long enough
to encompass multiple scheduled calibra-
tions. The present analysis examines the
results of a comprehensive study compar-
ing three CGM devices, the Navigator
(Abbott Diabetes Care), the Seven Plus
(DexCom), and the Guardian (Medtronic).
The study was conducted in subjects with
type 1 diabetes in a clinical research center
setting as part of closed-loop BG control
experiments. The three CGM devices were
worn simultaneously in each experiment
while reference-quality PG levels weremea-
sured every 15 min continuously for 48 h.
Results were analyzed in point accuracy
(including absolute and relative differ-
ences), rate-of-change accuracy, and sen-
sor reliability (including variation around
mean performance and data reporting
percentage).
RESEARCH DESIGN AND
METHODS
Subjects
The clinical protocol was approved by the
human research committees at Massachu-
setts General Hospital (MGH) and Boston
University. Six subjects with C-peptide–
deﬁcient, type 1 diabetes participated. All
subjects gave written informed consent. At
baseline, subjects were required to be aged
$18 years, to have had type 1 diabetes for
at least 1 year, and to have a stimulated C-
peptide level in response to a mixed-meal
tolerance test #0.1 nmol/L. The study co-
hort and the closed-loop experiments have
been described previously (4). Each subject
participated in two separate 48-h experi-
ments (96 h of data for each subject).
Experimental protocol
Subjects were admitted to the MGH
Clinical Research Center wearing Naviga-
tor, Seven Plus, and Guardian sensors and
transmitters, which were inserted the day
before the study at;1500 h according to
the respective manufacturers’ directions.
Upon admission, the three transmitters
were linked wirelessly to their respective
receiver devices.
Venous PG levels were measured
every 15 min with the GlucoScout (In-
ternational Biomedical) and conﬁrmed
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hourly with a YSI 2300 STAT Plus Ana-
lyzer (YSI Life Sciences). The three CGM
devices were calibrated according to the
manufacturers’ instructions, except that
venous PG rather than capillary self-
monitored BG (SMBG) values were used
for calibration. During each 48-h experi-
ment, the Navigator required one sched-
uled calibration, and the Seven Plus and
Guardian required four scheduled calibra-
tions. Beyond the usual scheduled calibra-
tions, any additional calibrations that were
requested by any CGM device were also
performed. In addition, if the CGMG read-
ing of any device did not meet the Inter-
national Organization for Standardization
standard for accuracy relative to PG at
0600 h daily, then a forced calibration of
that device was performed (see Supple-
mentary Data for further details).
Fully automated closed-loop BG con-
trol was initiated at 1500 h and ran
continuously for 51 h; the last 48 h of
each experiment were included in this
analysis. Six meals were provided during
this period; mean carbohydrate con-
sumption was 78 6 12 g (range 60–
117) per meal. Moderate exercise on a
stationary bicycle began 25 h into the ex-
periment and lasted ;30 min.
Accuracy, precision, and reliability
metrics
The point accuracy of each CGM device is
measured in terms of the relative differ-
ence (RD), deﬁned as [(CGMG 2 PG)/
PG], and the absolute relative difference
(ARD), deﬁned as [(CGMG 2 PG)/PG].
Negative RD values correspond to an un-
derestimation and positive values to an
overestimation of PG by the CGM device.
RD provides insight into the extent and
direction of bias in the estimation of PG
by a CGM device but is not as useful as
the ARD is in determining the average
error across a set of data because of the
cancelation that occurs when summing
positive and negative RD values.
The 48-h mean ARD (MARD) relative
to PG was calculated for each of the three
CGM devices during the 48-h period from
1800 h at the beginning of the ﬁrst day of
each experiment to 1800 h at the end of
the second day. The mean and SD of the
48-h MARD across the 12 experiments
are shown in Fig. 1B for each CGM de-
vice. Whereas the average of the 48-h
MARD characterizes the mean accuracy
of a particular sensor session in a given ex-
periment, the SD of this MARD provides a
precision metric of the variation around
mean accuracy from one sensor session
to another for each device. In essence, the
SD quantiﬁes the consistency relative to the
device’s average performance that can be
expected from one sensor to another for a
given CGM device.
In addition to assessing point accu-
racy, we evaluated the rate-of-change
accuracy of each of the three CGM devi-
ces. Reference rate-of-change data were
obtained by taking the difference between
two consecutive PG values and dividing
by the sampling interval between those
two PG measurements (typically 15 min).
Device reliability is measured with the
data reporting percentage, deﬁned as the
ratio of the number of glucose values
reported by the CGM receiver over the
48-h period relative to the total number
possible for that period. The three devices
were conﬁgured to record CGMG values
every 5 min. The Seven Plus, which has a
rechargeable battery that did not have
sufﬁcient capacity to power the device for
the entire experiment, was kept plugged
into its charging device.
Statistical analyses
Statistical analyses were performed using
SAS 9.2 software (SAS Institute Inc., Cary,
NC). Repeated-measurements models
were used forwithin-subject repeatedmea-
surements on the differences between the
paired measurements. This accounted for
within-subject correlations and correla-
tions in paired measurements. The
repeated-measurements models were ﬁtted
with the generalized estimating equation
method.
RESULTSdSix subjects (three men,
three women) each participated in two
51-h closed-loop BG control experi-
ments. Subjects weighed 72 6 10 (54–
85) kg, were aged 526 14 (33–72) years,
and had type 1 diabetes for 326 14 (17–
50) years.
CGM calibrations
No additional Navigator calibrations were
performed other than the scheduled
calibrations requested by the device
Figure 1dA: Representative results from one of twelve 48-h closed-loop BG control experiments
in one of six subjects showing venous PG concentrations measured every 15 min with the Glu-
coScout (red symbols) and CGMG values measured approximately every 5 min with the Navi-
gator (black symbols), Seven Plus (blue symbols), and Guardian (green symbols). The timing of
six meals is indicated by black triangles. One period of structured exercise at 1600 h (2 h before
the fourth meal) is indicated by a gray square. Listed in the legend for each CGM device is the
number (N) of glucose values measured, the data reporting percentage (in square brackets), and
the MARD averaged over the 48-h period, based on 194, 171, and 180 paired PG–CGMG values
for the Navigator, Seven Plus, and Guardian, respectively. B: The 48-h MARDs computed in each
of the 12 experiments are shown for each sensor, with the mean and SD of each of those MARDs
superimposed on the data for each device.
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Figure 2dClarke error grid analyses of venous plasma glucose (PG) measured by the GlucoScout (A), with venous BG measured by the YSI
designated as the reference, and CGMGmeasured by the Navigator (B), the Seven Plus (C), and the Guardian (D), with venous PGmeasured by the
GlucoScout designated as the reference. A: Based on a total of 597 GlucoScout–YSI glucose pairs, 98.3% of points fell in zone A and the remaining
1.7% fell in zone B. The slope and intercept of the linear least squares ﬁt to these data (solid red line) were 1.02 and 22 mg/dL, respectively. The
MARD was 5.1% between GlucoScout PG and YSI BG (after converting the latter to PG with a multiplicative factor of 1.12). B: Based on a total of
2,356 Navigator–GlucoScout pairs, the Navigator achieved 80.6% of points in zone A, 18.3% in zone B, 0% in zone C, and 1.0% in zone D. The slope
and intercept of the linear least squares ﬁt to these data (solid black line) were 0.71 and 33 mg/dL, respectively. The Navigator achieved an overall
data reporting percentage of 99.8% and aMARD of 11.86 11.1%.C: Based on a total of 1,799 Seven Plus–GlucoScout pairs, the Seven Plus achieved
76.2% of points in zone A, 22.7% in zone B, 0.9% in zone C, and 0.1% in zone D. The slope and intercept of the linear least squares ﬁt to these data
(solid blue line) were 1.02 and 1 mg/dL, respectively. The Seven Plus achieved an overall data reporting percentage of 76.2% and aMARD of 16.56
17.8%. D: Based on a total of 2,328 Guardian–GlucoScout pairs, the Guardian achieved 63.7% of points in zone A, 33.2% in zone B, 0.3% in zone
C, and 2.1% in zone D. The slope and intercept of the linear least squares ﬁt to these data (solid green line) were 0.77 and 26mg/dL, respectively. The
Guardian achieved an overall data reporting percentage of 98.6% and a MARD of 20.3 6 18.0%.
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Figure 3dA: Distribution, as a function of PG, of the RD between each CGMG measurement and its corresponding PG value (measured with the
GlucoScout) for the Navigator (black), Seven Plus (blue), and Guardian (green). B: Histograms in the PG–RD plane for each of the datasets shown
above in A. The horizontal line in each panel in A and the line in the PG–RD plane in each panel in B correspond to the MRD for each of the three
datasets. C: Distribution, as a function of PG, of the ARD between each CGMG measurement and its corresponding PG value (measured with the
GlucoScout) for the Navigator (black), Seven Plus (blue), and Guardian (green).D: Histograms in the PG–ARD plane for each of the datasets shown
in C. The horizontal line in each panel in C and the line in the PG–ARD plane in each panel in D correspond to the MARD for each of the three
datasets. Note, it can be seen that the data inC andD are derivable by reﬂecting all negatively valued RD data that fall below the PG axis inA and B to
their corresponding positive values above the PG axis. The ﬁve largest bins for the Navigator had frequencies of 96, 103, 105, 85, and 81 (all between
0 and 7% ARD) corresponding with PG values of 91–98, 98–105, 105–112, 112–119, and 119–126 mg/dL, respectively. These ﬁve bins collectively
contain 470 of the 2,356 data points (20%). The remaining bins had fewer than 60 hits each. Of the 2,356 data points, 940 (40%) fell in the bins with
0–7% ARD. The ﬁve largest bins for the Seven Plus had frequencies of 46, 48, 46, 43 (all between 0 and 7% ARD), and 44 (between 7 and 14% ARD)
corresponding with PG values of 98–105, 105–112, 112–119, 119–126, and 98–105 mg/dL, respectively. These ﬁve bins collectively contain 227 of
the 1,795 data points (12.6%). The remaining bins had fewer than 40 hits each. Of the 1,795 data points, 565 (31.5%) fell in the bins with 0–7%ARD.
The ﬁve largest bins for the Guardian had frequencies of 50, 58, 61, 53, and 56 (all between 0 and 7% ARD), corresponding with PG values of 91–98,
98–105, 105–112, 112–119, and 119–126 mg/dL, respectively. These ﬁve bins collectively contain 278 of the 2,324 data points (12%). The re-
maining bins had fewer than 50 hits each. Of the 2,324 data points, 569 (24.5%) fell in the bins with 0–7% ARD.
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(corresponding to one calibration during
the 2-day duration of each experiment);
the ﬁnal 41–42 h of each experiment were
performed without any calibrations of the
Navigator. The scheduled calibrations of
the Seven Plus and Guardian occurred ap-
proximately every 12 h; therefore, four
calibrations occurred during the 2-day du-
ration of each experiment. An average of
4.7 (4–6) calibrations per experiment
were performed for the Guardian (see
Supplementary Data for further details).
CGM point accuracy
The 48-h MARD for the Navigator was
11.8 6 3.8% compared with 16.5 6
6.7% for the Seven Plus (z = 22.05, P =
0.040) and 20.26 6.8% for the Guardian
(z =23.14, P = 0.002). The 48-h MARDs
for the Seven Plus and Guardian were not
signiﬁcantly different (z = 21.17, P =
0.240).
The point accuracy for each CGM
device is shown as Clarke error grids in
Fig. 2 and as RD and ARD distributions in
Fig. 3. The aggregate MARD across the
2,356 paired points obtained with the
Navigator was 11.8 6 11.1% compared
with an aggregate MARD of 16.5 6
17.8% for the 1,799 paired points ob-
tained with the Seven Plus (z = 21.62,
P = 0.110 vs. Navigator), and 20.3 6
18.0% for the 2,328 paired points obtained
with theGuardian (z =23.07, P = 0.002 vs.
Navigator). The aggregate MARDs for the
Seven Plus and Guardian were not signiﬁ-
cantly different (z =21.31, P = 0.190). To
put these MARD values in perspective, we
calculated the maximum bound on the
MARDs for each of the three devices by
randomly shufﬂing the paired CGMG
and PG values for each dataset and recal-
culating the MARDs (see Supplementary
Data for details). This procedure yielded
upper bounds on the MARD of 41% for
the Navigator, 54% for the Seven Plus,
and 47% for the Guardian. We estimate
that the lower bound of the possible
MARD values would be 5.1%, the MARD
of the reference quality GlucoScout device
relative to the reference quality YSI Stat
Plus Glucose monitor when measuring
the same sample.
The RD distributions are shown in
Fig. 3A. In the case of the Navigator, 13 of
2,356 points had positive RD values
.50% (range 51–167%). Of these 13
points (PG range 36–135 mg/dL), 6 cor-
responded to PG values ,70 mg/dL, and
all PG values,76 mg/dL had positive RD
values. Thus, the Navigator consistently
overestimated PG in the hypoglycemic
range; conversely, there were no negative
Navigator RD values .50% (243% was
the most negative RD value). Data in the
hyperglycemic range accounted for the
most negative RD values; 92% of points
with PG values.250 mg/dL had negative
RD values for the Navigator. Thus, the
Navigator tends to underestimate PG in
the hyperglycemic range. With the Seven
Plus, 48 of 1,795 points had RD values
.50% (51–247%), but these were dis-
tributed over a much broader range of
PG values (36–261 mg/dL) than with
the Navigator. The Guardian had even
more points (78 of 2,324) with RD values
.50% (50–143%), and like the Seven Plus,
these were distributed over amuch broader
range of PG values (49–257 mg/dL) than
with the Navigator. Like the Navigator, the
Guardian also tended to underestimate PG
in the hyperglycemic range, with 77% of
PG values .250 mg/dL having negative
RD values. This was not the case for the
Seven Plus, where only 45% of PG values
.250 mg/dL had negative RD values,
showing essentially no bias in the hypergly-
cemic range.
This lack of bias in the Seven Plus data
is also evident in the near-unity slope
(1.02) of the linear least squares ﬁt (Fig.
2C). By comparison, the slopes of the lin-
ear least squares ﬁt are 0.71 for the Nav-
igator and 0.77 for the Guardian (Fig. 2B
and D), which is consistent with the bias
in those two devices to underestimate PG
in the hyperglycemic range and, to a lesser
extent, overestimate PG in the hypoglyce-
mic range. This bias in the Navigator and
Guardian devices is further evident in the
underestimation in the mean PG obtained
from each device. The mean PG across
the 12 experiments as measured by the
GlucoScout was 158 6 20 mg/dL; the
Navigator and Guardian underestimated
the mean PG by 13 mg/dL (1456 17, z =
23.78, P = 0.0002) and 12mg/dL (1466
26, z =23.62, P = 0.0003), respectively,
whereas the Seven Plus overestimated the
mean PG by 5 mg/dL (1636 24, z = 2.67,
P = 0.0075).
Owing to the high data density in the
distributions shown in Fig. 3A and C, par-
ticularly over the range of PG values be-
tween 80 and 160 mg/dL, it is instructive
to collect the data into frequency bins in
the PG–RD plane of Fig. 3A and in the
PG–ARD plane of Fig. 3C and generate
histograms over the PG–RD plane (Fig.
3B) and PG–ARD plane (Fig. 3D), respec-
tively. For the bin sizes shown in Fig. 3B
and D (which span 7% by 7 mg/dL in the
PG–RD and PG–ARD planes), the
Navigator had bins with the highest num-
ber of PG–RD and PG–ARD pairs. Relative
to the data obtained from the Seven Plus
and Guardian, the data obtained from the
Navigator are much more concentrated in
the 0–7% error bins and show much less
dispersion over the PG–RD and PG–ARD
planes (Fig. 3), demonstrating graphically
the greater accuracy and precision of Nav-
igator estimates of PG.
When the MARD is calculated for the
clinically relevant PG ranges of 70–120,
120–180, and 180–250 mg/dL (Fig. 4D),
the Navigator outperformed the other
two devices in MARD and SD of the
MARD. Its performance was relatively
better in the 70 to 120 mg/dL range
than in the 180 to 250 mg/dL range, but
the Seven Plus andGuardian each showed
relatively similar performance across the
three PG ranges, with the former outper-
forming the latter in a mean sense in all
three.
CGM rate-of-change accuracy
We also evaluated the time-rate-of-
change accuracy for each of the three
CGM devices. Rate-of-change measure-
ments from the reference PG data yielded
1,699 slopes from the twelve 48-h ex-
periments. Similarly, time-rate-of-change
data corresponding to these 1,699 refer-
ence values were extracted from the CGM
data. The absolute value of the difference
between the PG slopes and each of the
corresponding CGM slopes was com-
puted and averaged over the 1,699 paired
slopes for all three CGM devices. On
average, the time-rate-of-change error
(relative to PG) for the Navigator was
0.66 6 0.96 mg/dL/min compared with
0.866 1.20mg/dL/min for the Seven Plus
(z = 22.94, P = 0.003 vs. Navigator) and
0.86 6 1.26 mg/dL/min for the Guardian
(z =22.60, P = 0.009 vs. Navigator). The
time-rate-of-change errors for the Seven
Plus and Guardian were not signiﬁcantly
different (z = 0.01, P = 0.990). Figure 5
shows, for each of the three CGM devices,
the absolute value of the time-rate-of-
change error sorted into eight bins, where
each bin includes all paired points in a
particular range of absolute values of the
time rate of change in PG. The largest
physiological rise and fall in PG that we
observed over a 15-min interval was 8.1
and 7.3 mg/dL/min, respectively.
CGM precision and reliability
When the mean and SD of all PG–ARD
pairs associated with a particular PG value
were computed for each PG value
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between 70 and 320 mg/dL (Fig. 4A–C),
the average SD at each PG value wasmuch
smaller for the Navigator (8.86 3.9) than
for the Seven Plus (13.9 6 8.7) and the
Guardian (15.1 6 7.4), indicative of
higher precision of the Navigator relative
to the other two devices.
Occasionally, glucose values will be
skipped during online operation of a
CGM. When averaged across the 12 ex-
periments, the data reporting per-
centages were 99.8 6 0.6% for the
Navigator, 75.9 6 20.7% for the Seven
Plus, and 98.5 6 2.5% for the Guardian.
Data reporting percentages for the three
CGM devices for each experiment are
provided in the legends of Supple-
mentary Figs. 1–12.
CONCLUSIONSdResults from this
head-to-head-to-head analysis of three
commercially available CGM devices
worn simultaneously by each subject for
2 days under the same experimental con-
ditions are in remarkably good agreement
with the results of studies reported in the
manufacturers’ own labeling. However,
the direct comparison of the three CGM
devices over a broad range of PG values is
unique and, we think, compelling. The
manufacturers’ user guides for each of
these devices report MARDs (relative to
YSI BG measurements) of 12.8 6 13.6%
for the Navigator for 20,362 paired glu-
cose values $20 mg/dL (compared with
11.8 6 11.1% for 2,356 paired points in
the current study), 16% for the Seven Plus
for 1,827 paired glucose values between
40 and 400 mg/dL (compared with
16.5 6 17.8% for 1,799 paired points in
the current study), and 19.76 18.4% for
the Guardian for 3,941 paired glucose
values $40 mg/dL (compared with
20.3 6 18.0% for 2,328 paired points in
the current study). Thus, the manufactur-
ers’ labeling for point accuracy is consis-
tent with our ﬁndings in a direct
comparison study, despite inevitable dif-
ferences in study populations and condi-
tions between the different manufacturers
studies.
The clinical utility of the CGM devi-
ces, especially when applied to closed-
loop BG control, depends not only on
device accuracy but also on reliability.
Interruption in the glucose data stream
under open-loop glucose management re-
quires the user to revert to SMBG therapy
without trend information until data re-
porting resumes. Under automated closed-
loop BG control, such interruptions would
take the closed-loop system ofﬂine. Of the
three CGM devices studied here, only the
Seven Plus seemed prone to gaps in data
reporting. Another metric of reliability is
precision, as measured by the variability
Figure 4dA–C: The MARD and SD in the MARD corresponding to each PG value from 70 to 320 mg/dL for the Navigator, Seven Plus, and
Guardian, respectively. Data points without error bars represent sole values for that particular PG value. D: The MARD and SD in the MARD
corresponding to the clinically relevant PG ranges from 70–120, 120–180, 180– 250, and$250mg/dL for the Navigator, Seven Plus, andGuardian.
The number (N) of data in each PG range is shown in the corresponding bar for each device. For PG values in the normoglycemic range, from 70 to
120 mg/dL, the MARDs were 9.1 6 9.3% (N = 899), 16.5 6 17.8% (N = 677), and 20.0 6 19.9% (N = 889), for the Navigator, Seven Plus, and
Guardian, respectively. Much less reliable, because of the small sample size obtained, are the data corresponding to PG values in the moderate-to-
mild hypoglycemic range from 50 to 70 mg/dL (not shown here); in this range, the MARDs were 466 33% (N = 14), 316 25% (N = 11), and 366
40% (N = 14), for the Navigator, Seven Plus, and Guardian, respectively.
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around mean performance. This was quan-
tiﬁed here by the SD around the aggregate
mean of all ARD values and around the
mean of ARD values from each individual
experiment from each CGM device. The
latter confers information about the variation
in performance of a CGM device from one
sensor session to another andmay be amore
clinically useful concept than the SD around
the aggregate mean. The Navigator variabil-
ity was approximately one-half that of the
other two CGM devices for both metrics.
In essentially every respect (aggregate
MARD, MARD per experiment, precision,
distribution of relative errors in the PG–
RD plane, rate-of-change errors, and data
reporting frequency), the results of the
current study point to the Navigator as
having the best performance in the nor-
moglycemic and hyperglycemic range.
Although the Guardian had comparable
performance to the Navigator in data re-
porting frequency, it had numerically the
worst performance for most of the metrics
analyzed. Our conclusions about perfor-
mance in the normoglycemic range are
qualitatively and quantitatively different
from those of a previous study that di-
rectly compared the accuracy of the Nav-
igator and Guardian devices in the setting
of a short-term glucose clamp study (3).
That study concluded that the accuracy of
the Guardian and Navigator was compa-
rable in the normoglycemic range (3). All
of their data were collected when the
BG was clamped at 100 or 45 mg/dL, or
during a slow transition (at a rate of 1 mg/
dL/min) between these two BG values.
Thus, no data were collected in the hy-
perglycemic range, and the effect of phys-
iologic lag on accuracy was minimized by
the negligible or low time rates of change
in BG during the measurement period. In
contrast, our data include many compar-
isons in the hyperglycemic range, and we
sampled a much broader range of rates of
change of BG (up to –7 and +8 mg/dL/
min for short periods of time). Further,
the number of paired BG-CGMG points
in the normoglycemic range was at least
threefold greater than in the study of
Kovatchev et al. (3), and each experiment
was much longer, allowing us to observe
sensor inaccuracies associated with sen-
sor drift, which is a common source of
error for CGM devices. Finally, the study
of Kovatchev et al. (3) did not show, as
we did, the degree of variability in the
accuracy of each sensor, a critical deter-
minant of its reliability. Therefore, the re-
sults of our study are more informative
regarding the suitability of each CGM de-
vice as the input sensor for closed-loop
BG control.
One of the purposes of this head-to-
head-to-head comparison study was to
determine whether the Seven Plus and/or
Guardian could substitute for the Navi-
gator in closed-loop BG control. In the
closed-loop experiments from which
these data are derived (4), the Navigator
served as the sole input to a fully autono-
mous system that successfully regulated
BG continuously over a 2-day period (av-
erage PG of 158 mg/dL, with PG,70 mg/
dL,0.7% of the time) (4). Other closed-
loop studies have used the Seven Plus or
Guardian and reported MARDs for those
devices that were much better than the
MARDs we found for those devices in
this study and were comparable to the
MARD we found for the Navigator (5–
9). However, some of these studies report
switching betweenmultiple sensors based
on reference data and/or calibrating sen-
sors more frequently than recommended
by the manufacturer (on average every 4–
6 h) (7–9), while the others report inserting
two sensors on each subject (5,6) without
providing details about when and if switch-
ing between sensors occurred.
High-frequency calibrations are im-
practical in outpatient usage, and switch-
ing between multiple sensors based on
frequently sampled BG undermines sys-
tem autonomy; results of experiments
using these strategies will not be repre-
sentative of system performance in rou-
tine outpatient usage. Thus, it is not clear
whether the Seven Plus or Guardian devi-
ces are accurate or reliable enough to serve
as the sole input to an autonomous closed-
loop BG control system when calibrated
at a practical clinical frequency and op-
erating without the beneﬁt of frequently
sampled BG to monitor their accuracy.
Evidence that the Seven Plus or Guardian
devices may not meet this standard was
apparent in several of the experiments
conducted in this study. There were re-
peated instances during which the Seven
Plus and Guardian devices showed aber-
rant behavior that would likely have led a
control algorithm to severely underdose
insulin on some occasions and to severely
overdose on others. There were three
occasions each for the Seven Plus and
Guardian when the devices overestima-
ted the subject’s glucose by $70 mg/dL
for a period of 1–5 h (Supplementary
Figs. 2 and 12 for the Seven Plus and
Supplementary Figs. 1 and 12 for the
Guardian), which would have resulted
in overdosing insulin. Conversely, we ob-
served one occasion for the Seven Plus
(Supplementary Fig. 1) and seven for
Figure 5dThe absolute value of the difference between the time rate of change in CGMG and the
time rate of change in PG corresponding to eight different ranges in the absolute value of the time
rate of change in PG (0–0.25, 0.25–0.5, 0.5–0.75, 0.75–1, 1–1.5, 1.5–2, 2–3, and $3 mg/dL/
min) for the Navigator, Seven Plus, and Guardian. The number (N) of data in each range is shown
below the range label.
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the Guardian (Supplementary Figs. 1, 2,
7, 9, and 10) when the devices failed to
detect large postprandial glucose excur-
sions around meals, and underdosing in-
sulin would have resulted. Finally, we
observed one occasion for the Seven
Plus (Supplementary Fig. 1) and three oc-
casions for the Guardian (Supplementary
Figs. 1, 2, and 6) when the devices falsely
predicted severe hypoglycemia for$3 h.
One of the limitations of our analysis
was that the data were collected as part
of a closed-loop study and, therefore,
contained relatively few points ,70 and
.250 mg/dL. Glucose values were thus
concentrated in a narrower range than
typically arises in standard-of-care type
1 diabetes therapy. In particular, our
data do not allow us to assess the accuracy
of the three sensors in the hypoglycemic
range (BG,70mg/dL).When comparing
the accuracy of the Guardian and Naviga-
tor, Kovatchev et al. (3) concluded that
the Navigator had better accuracy in the
hypoglycemic range. However, that study
censored data in the hypoglycemic range
whenever the CGMG was at the low
threshold for that CGM device and was
not changing with respect to time (3).
Furthermore, different percentages of
the data were censored for the two sensors
(3). This approach undermines the appli-
cability of their analysis to closed-loop
control because a control decision must
be rendered at each time step under
closed loop.
Another limitation of our work is that
although the timing of calibrations was
strictly followed according to the manu-
facturers’ speciﬁcations, the calibrations
were done using reference-quality PG
rather than capillary SMBG measure-
ments. These factors could have led us
to overestimate the accuracy of the CGM
devices when used as a part of current
standard-of-care therapy.
An additional limitation is that our
dataset, although containing a large num-
ber of BG-CGMG pairs, was collected
from 12 experiments in six subjects and
therefore may not sample as much bi-
ological variability as a study in which
fewer measurements were collected from
each of a larger number of participants. A
post hoc analysis revealed that there was
nearly as much variation in the accuracy
ranking of the three CGM devices be-
tween experiments in a single subject as
there was between subjects, suggesting
that the results were not due to the chance
inclusion of subjects who idiosyncratically
were capable of achieving better perfor-
mance with one sensor than another (data
not shown).
Although the performance differen-
ces we observed between the Seven Plus
and Guardian are not as pronounced as
between the Navigator and Seven Plus,
the Seven Plus demonstrates consistently
better point accuracy and comparable
rate-of-change accuracy compared with
the Guardian. However, an evident dis-
advantage of the Seven Plus relative to the
Guardian lies in its lower data reporting
frequency. This weakness is less critical
under open-loop than under closed-loop
control. According to Dexcom representa-
tives, leaving the receiver device plugged
in to its charger during the experiments
might have contributed to the poor re-
porting frequency. However, we observed
that gaps in reporting were not randomly
distributed but tended much more often
to occur during times when the Seven Plus
CGMG was changing rapidly (typically
.2 mg/dL/min), suggesting that loss of
reporting may be related to ﬁlters in the
BG estimation algorithm.
The results of this head-to-head-to-
head comparative effectiveness study re-
veal the Navigator was the most accurate
and precise of the current generation of
CGM devices, followed by the Seven Plus
and the Guardian. Integration of the Nav-
igator into a truly autonomous closed-loop
BG control system provides a demonstra-
tion of the clinical utility of theNavigator in
driving that system (4). Combining those
ﬁndings with results of the current study
provides quantitative benchmarks for ac-
curacy and reliability for a CGM device to
serve as sole input for a closed-loop BG
control system. Further study is required
to determine whether the Seven Plus or
Guardian, calibrated according to manu-
facturer’s directions, would be sufﬁciently
accurate and reliable for effective closed-
loop BG control in a clinical protocol that
does not undermine the autonomy of the
system by acting on the knowledge of fre-
quently sampled PG values. In light of the
results of our analysis, it is unfortunate
that the manufacturer has recently with-
drawn the Navigator from the North
American market. We are currently using
the same methodology described in this
report to compare the performance of
the next-generation Navigator with the
next-generation devices from DexCom
and Medtronic.
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